The Effects of Intravenous Immunoglobulin on Coronary Artery Abnormalities in Children With Kawasaki Disease

Document Type : Original Article


1 Children and Adolescent Health Research Center, Research Institute of cellular and Molecular Science in Infectious Diseases , Zahedan University of Medical Science's, Zahedan, IR Iran.

2 Department of Population Study, School of Sociology, Islamic Azad University of Iran, Central Tehran Branch, Tehran, IR Iran.


Background: Kawasaki disease (KD) is an acute systemic vasculitis in childhood, with a strong effect on the heart. The present study aimed to evaluate the effects of intravenous immunoglobulin (IVIG) on coronary artery abnormalities in children with KD.
Methods: This study was performed on 101 children with KD between 2004 and 2019. Echocardiography was used to assess coronary artery abnormalities. A coronary artery was considered abnormal if the internal lumen diameter exceeded 2 mm in infants, 3 mm in children aged between 2 and 5 years, and 4 mm in children older than 5 years. Data analysis was done using the SPSS software, version 22. A P value less than 0.05 was considered statistically.
Results: Before IVIG administration, abnormal left coronary arteries were reported in 21 children. However, 2, 6, and 12 months following IVIG administration, the number of children with left coronary artery abnormalities dropped to 5, 2, and 1, respectively.  Before IVIG administration, abnormal right coronary arteries were reported in 13 patients. Nonetheless, 2, 6, and 12 months after IVIG administration, the number of patients with right coronary artery abnormalities fell to 5, 1, and 1, respectively.
Conclusions: IVIG administration in our children with KD significantly affected left and right coronary artery abnormalities after 6 months, with the effect being stronger in the left coronary artery. (Iranian Heart Journal 2022; 23(1): 172-183)


  1. Dyer T, Dancey P, Martin J, Shah S. Torticollis as Presentation for Atypical Kawasaki Disease Complicated by Giant Coronary Artery Aneurysms. Case reports in pediatrics. 2018; 2018.
  2. Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child.2015;100(11):10848.
  3. Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S, Aoyama Y, Kojo T, Uehara R, Kotani K, Yanagawa H. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015; 25(3):23945.
  4. Kim GB, Park S, Eun LY, Han JW, Lee SY, Yoon KL, Yu JJ, Choi JW, Lee KY. Epidemiology and clinical features of Kawasaki disease in South Korea, 2012–2014. The Pediatric infectious disease journal. 2017 May 1; 36(5):482-5.
  5. Wu MH, Lin MT, Chen HC, Kao FY, Huang SK. Postnatal risk of acquiring Kawasaki disease: a nationwide birth cohort database study. J Pediatr. 2017; 180:8086.e2.
  6. Ozdemir H, Ciftci E, Tapisiz A, Ince E, Tutar E, Atalay S, Dogru U. Clinical and epidemiological characteristics of children with Kawasaki disease in Turkey. J Trop Pediatr. 2010; 56(4):2602.
  7. Asadi-Pooya AA, Borzoee M, Amoozgar H. The experience with 113 patients with Kawasaki disease in Fars Province, Iran. Turk J Pediatr. 2006; 48(2):109114.
  8. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, Baker AL, Jackson MA, Takahashi M, Shah PB, Kobayashi T. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017 Apr 25; 135(17):e927-99.
  9. Chaiyarak K, Durongpisitkul K, Atta T, Soongswang J, Laohaprasitiporn D, Nana A. Clinical manifestations of Kawasaki disease: what are the significant parameters?. Asian Pacific journal of allergy and immunology. 2009 Jun 1; 27(2-3):131.
  10. Campbell AJ, Burns JC. Adjunctive therapies for Kawasaki disease. Journal of Infection. 2016; 72:S1-5.
  11. Menikou S, Langford PR, Levin M. Kawasaki disease: the role of immune complexes revisited. Frontiers in immunology. 2019; 10.1156.
  12. Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. PediatrRheumatol Online J. (2014) 12:26. doi: 10.1186/1546-0096-12-26.
  13. Noguchi S, Saito J, Kudo T, Hashiba E, Hirota K. Safety and efficacy of plasma exchange therapy for Kawasaki disease in children in intensive care unit: Case series. JA clinical reports. 2018 Dec 1; 4(1):25.
  14. Lin MT, Wu MH. The global epidemiology of Kawasaki disease: Review and future perspectives. Global cardiology science & practice. 2017 Oct 31; 2017(3).
  15. Song MS. Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease. Korean journal of pediatrics. 2019 Apr;62(4):119.
  16. Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. The Journal of pediatrics. 2000 Aug 1; 137(2):250-2.
  17. Kil HR, Yu JW, Lee SC, Rhim JW, Lee KY. Changes in clinical and laboratory features of Kawasaki disease noted over time in Daejeon, Korea. Pediatric Rheumatology. 2017 Dec; 15(1):60.
  18. Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease. Pediatric Rheumatology. 2019 Dec 1; 17(1):53.
  19. Bal AK, Prasad D, Pamintuan MA, Mammen-Prasad E, Petrova A. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease. Pediatrics & Neonatology. 2014 Oct 1; 55(5):387-92.
  20. Binder E, Griesmaier E, Giner T, Sailer-Höck M, Brunner J. Kawasaki disease in children and adolescents: clinical data of Kawasaki patients in a western region (Tyrol) of Austria from 2003–2012. Pediatric Rheumatology. 2014 Dec;12(1):37.
  21. Li X, Chen Y, Tang Y, Ding Y, Xu Q, Sun L, Qian W, Qian G, Qin L, Lv H. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases. European journal of pediatrics. 2018 Aug 1; 177(8):1279-92.
  22. Shah SA, Mahmud S. KAWASAKI DISEASE EXPERIENCE AT TERTIARY CARE HOSPITAL RAWALPINDI, PAKISTAN. Pakistan Armed Forces Medical Journal. 2018 Oct 1(5):1143.48
  23. Muta H, Ishii M, Yashiro M, Uehara R, Nakamura Y. Late intravenous immunoglobulin treatment in patients with Kawasaki disease. Pediatrics. 2012; 129:e291–7.
  24. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113:2606–2612.
  25. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356:663- 75
  26. Keum SW, Hur SM, Youn YS, Rhim JW, Suh JS, Lee KY, et al Changes in acute poststreptococcal glomerulonephritis: an observation study at a single Korean hospital over two decades. Child Kidney Dis. 2015; 19:112–7.
  27. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149:237–240.
  28. Oates‐Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews. 2003(4).